Immunotherapy of cancer in 2012
2012/05/10 by John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini +5 · 26 citations
Immunology and Microbiology · Medicine · #Immunotherapy and Immune Responses #Cancer Immunotherapy and Biomarkers #Immune Cell Function and Interaction
paper · doi:10.3322/caac.20132
Abstract
The immunotherapy of cancer has made significant strides in the past few years due to improved understanding of the underlying principles of tumor biology and immunology. These principles have been critical in the development of immunotherapy in the laboratory and in the implementation of immunotherapy in the clinic. This improved understanding of immunotherapy, enhanced by increased insights into the mechanism of tumor immune response and its evasion by tumors, now permits manipulation of this interaction and elucidates the therapeutic role of immunity in cancer. Also important, this improved understanding of immunotherapy and the mechanisms underlying immunity in cancer has fueled an expanding array of new therapeutic agents for a variety of cancers. Pegylated interferon-α2b as an adjuvant therapy and ipilimumab as therapy for advanced disease, both of which were approved by the United States Food and Drug Administration for melanoma in March 2011, are 2 prime examples of how an increased understanding of the principles of tumor biology and immunology have been translated successfully from the laboratory to the clinical setting. Principles that guide the development and application of immunotherapy include antibodies, cytokines, vaccines, and cellular therapies. The identification and further elucidation of the role of immunotherapy in different tumor types, and the development of strategies for combining immunotherapy with cytotoxic and molecularly targeted agents for future multimodal therapy for cancer will enable even greater progress and ultimately lead to improved outcomes for patients receiving cancer immunotherapy.
Cited by
- Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
- Cancer genome landscapes. [europepmc]
- Evolutionary dynamics of cancer in response to targeted combination therapy. [europepmc]
- The Yin and Yang of Toll-like receptors in cancer. [europepmc]
- Adoptive immunotherapy for cancer or viruses. [europepmc]
- Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. [europepmc]
- CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. [europepmc]
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. [europepmc]
- Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. [europepmc]
- Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. [europepmc]
- H1N1 influenza virus infection results in adverse pregnancy outcomes by disrupting tissue-specific hormonal regulation. [europepmc]
- Systemic treatments for metastatic cutaneous melanoma. [europepmc]
- Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. [europepmc]
- Current and Emerging Targets in Immunotherapy for Osteosarcoma. [europepmc]
- PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway. [europepmc]
- Harnessing radiation to improve immunotherapy: better with particles? [europepmc]
- Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. [europepmc]
- Cancer Cell Membrane-Coated Nanoparticles for Cancer Management. [europepmc]
- Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. [europepmc]
- Carbon Ion Radiobiology. [europepmc]
- Bioengineered bacteria-derived outer membrane vesicles as a versatile antigen display platform for tumor vaccination via Plug-and-Display technology. [europepmc]
- Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. [europepmc]
- Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. [europepmc]
- Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. [europepmc]
- Cancer Spheroids and Organoids as Novel Tools for Research and Therapy: State of the Art and Challenges to Guide Precision Medicine. [europepmc]
- Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. [europepmc]
Related